<p>周四，uniQure 的股票在 FDA 表示缺乏足够证据批准其亨廷顿基因疗法的消息后，经历了显著下跌。FDA 的拒绝导致 uniQure 的股票再次下跌，表明公司面临严峻的挑战。这一消息突显了 uniQure 亨廷顿病治疗前景的不确定性。</p>

QURE

<p>在周四，UniQure 的股票在 FDA 表示缺乏足够证据以批准其亨廷顿基因疗法的消息后，经历了显著下跌。FDA 的拒绝导致 UniQure 的股票再次下跌，表明该公司面临着严峻的局面。这一消息突显了围绕 UniQure 亨廷顿病治疗前景的不确定性</p>

<p>On Thursday, UniQure stock experienced a significant decrease following news that the FDA has stated insufficient evidence for the approval of their Huntington's gene therapy. The rejection from the FDA has caused another drop in UniQure's stock, indicating a challenging situation for the company. This news emphasizes the uncertainty surrounding the fate of UniQure's treatment for Huntington's disease.</p>
<div class="lb-trans"><p>周四，uniQure 的股票在 FDA 表示缺乏足够证据批准其亨廷顿基因疗法的消息后，经历了显著下跌。FDA 的拒绝导致 uniQure 的股票再次下跌，表明公司面临严峻的挑战。这一消息突显了 uniQure 亨廷顿病治疗前景的不确定性。</p>
</div>

由于 FDA 表示证据不足以批准亨廷顿病的治疗，UniQure 的股票大幅下跌